Spero Therapeutics Inc, a biopharmaceutical company, is working to combat multi-drug resistant bacterial infections, but its financial indicators and market volatility raise questions about its stability and growth potential.

Spero Therapeutics’ stock price surged by over 200% after a clinical trial for its antibiotic treatment, tebipenem HBr, showed promising results and was stopped early due to efficacy.

Spero Therapeutics, a biopharmaceutical company, is pioneering the fight against multi-drug resistant bacterial infections with innovative treatments and a commitment to addressing the urgent need for new antibiotics.